menu
    • menu
    [{"orgOrder":0,"company":"Biocon Biologics","sponsor":"Eris Lifesciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"INDIA","productType":"Small molecule","year":"2023","type":"Divestment","leadProduct":"Everolimus","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Biocon Biologics","amount2":0.040000000000000001,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0.040000000000000001,"dosageForm":"Tablet","sponsorNew":"Biocon Biologics \/ Eris Lifesciences","highestDevelopmentStatusID":"12","companyTruncated":"Biocon Biologics \/ Eris Lifesciences"},{"orgOrder":0,"company":"Biocon Biologics","sponsor":"Sandoz B2B","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"INDIA","productType":"Large molecule","year":"2024","type":"Partnership","leadProduct":"Trastuzumab","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Biocon Biologics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Biocon Biologics \/ Sandoz","highestDevelopmentStatusID":"12","companyTruncated":"Biocon Biologics \/ Sandoz"},{"orgOrder":0,"company":"Biocon Biologics","sponsor":"Eris Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"INDIA","productType":"Small molecule","year":"2024","type":"Collaboration","leadProduct":"Metoprolol Succinate","moa":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Biocon Biologics","amount2":0.14999999999999999,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0.14999999999999999,"dosageForm":"Prolonged Release Tablet","sponsorNew":"Biocon Biologics \/ Eris Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Biocon Biologics \/ Eris Pharmaceuticals"},{"orgOrder":0,"company":"Biocon Biologics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"INDIA","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"Aflibercept","moa":"","graph1":"Ophthalmology","graph2":"Approved","graph3":"Biocon Biologics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"","sponsorNew":"Biocon Biologics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Biocon Biologics \/ Not Applicable"},{"orgOrder":0,"company":"Biocon Biologics","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"INDIA","productType":"Large molecule","year":"2024","type":"Licensing Agreement","leadProduct":"Ustekinumab","moa":"","graph1":"Dermatology","graph2":"Approved","graph3":"Biocon Biologics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"","sponsorNew":"Biocon Biologics \/ Johnson & Johnson Innovative Medicine","highestDevelopmentStatusID":"12","companyTruncated":"Biocon Biologics \/ Johnson & Johnson Innovative Medicine"},{"orgOrder":0,"company":"Biocon Biologics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"Ustekinumab","moa":"","graph1":"Dermatology","graph2":"Approved","graph3":"Biocon Biologics","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"","sponsorNew":"Biocon Biologics \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Biocon Biologics \/ Not Applicable"},{"orgOrder":0,"company":"Biocon Biologics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"INDIA","productType":"Antibody","year":"2025","type":"Inapplicable","leadProduct":"Ustekinumab","moa":"IL-12\/IL-23","graph1":"Dermatology","graph2":"Approved FDF","graph3":"Biocon Biologics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Biocon Biologics \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Biocon Biologics \/ Inapplicable"}]

    Find Clinical Drug Pipeline Developments & Deals by Biocon Biologics

    Menu

    Biocon Biologics

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Biocon Biologics

                            India arrow
                            BioAsia
                            Not Confirmed

                            Biocon Biologics

                            India arrow
                            BioAsia
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ustekinumab

                            Therapeutic Area : Dermatology

                            Study Phase : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Biocon Biologics’ Ustekinumab BS Approved by Japan Health Authority

                            Details : Yesintek (ustekinumab), is an approved IL-12/IL-23 inhibitor is given once in 12 weeks SC and IV for the treatment of moderate to severe plaque psoriasis in patients with 6 years or older.

                            Product Name : Yesintek

                            Product Type : Antibody

                            Upfront Cash : Inapplicable

                            January 07, 2025

                            Lead Product(s) : Ustekinumab

                            Therapeutic Area : Dermatology

                            Highest Development Status : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Biocon Biologics

                            India arrow
                            BioAsia
                            Not Confirmed

                            Biocon Biologics

                            India arrow
                            BioAsia
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ustekinumab

                            Therapeutic Area : Dermatology

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Biocon Biologics Receives FDA Approval for Biosimilar YESINTEK

                            Details : Yesintek (ustekinumab), is an approved IL-12/IL-23 inhibitor is given once in 12 weeks SC and IV for the treatment of moderate to severe plaque psoriasis in patients with 6 years or older.

                            Product Name : Yesintek

                            Product Type : Large molecule

                            Upfront Cash : Not Applicable

                            December 02, 2024

                            Lead Product(s) : Ustekinumab

                            Therapeutic Area : Dermatology

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Biocon Biologics

                            India arrow
                            BioAsia
                            Not Confirmed

                            Biocon Biologics

                            India arrow
                            BioAsia
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ustekinumab

                            Therapeutic Area : Dermatology

                            Study Phase : Phase III

                            Sponsor : Johnson & Johnson Innovative Medicine

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Biocon Settles with Janssen to Commercialise Biosimilar Products in Europe, Canada, Japan

                            Details : The agreement aims to commercialize its Bmab 1200, a proposed biosimilar to Stelara and a monoclonal antibody medication, in Europe, the United Kingdom (UK), Canada, and Japan.

                            Product Name : Bmab 1200

                            Product Type : Large molecule

                            Upfront Cash : Undisclosed

                            August 29, 2024

                            Lead Product(s) : Ustekinumab

                            Therapeutic Area : Dermatology

                            Highest Development Status : Phase III

                            Sponsor : Johnson & Johnson Innovative Medicine

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Biocon Biologics

                            India arrow
                            BioAsia
                            Not Confirmed

                            Biocon Biologics

                            India arrow
                            BioAsia
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Aflibercept

                            Therapeutic Area : Ophthalmology

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Biocon Biologics gets FDA nod for Yesafili™, enters U.S. ophthalmology market

                            Details : Yesafili (aflibercept) is a PGF & VEGF-A inhibitor, its single-dose vial formulation is approved for the treatment of neovascular (wet) age-related macular degeneration and diabetic macular edema.

                            Product Name : Yesafili

                            Product Type : Large molecule

                            Upfront Cash : Not Applicable

                            May 21, 2024

                            Lead Product(s) : Aflibercept

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Biocon Biologics

                            India arrow
                            BioAsia
                            Not Confirmed

                            Biocon Biologics

                            India arrow
                            BioAsia
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Metoprolol Succinate

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Approved

                            Sponsor : Eris Pharmaceuticals

                            Deal Size : $150.0 million

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            India's Biocon to sell branded formulations business to Eris Lifesciences for $150 mln

                            Details : The collaboration aims to support the Biocon for the commercialization of ACTIBLOK IPR 25 (metoprolol succinate). It is an approved product indicated for hypertension and angina pectoris.

                            Product Name : ACTIBLOK IPR 25

                            Product Type : Small molecule

                            Upfront Cash : Undisclosed

                            March 13, 2024

                            Lead Product(s) : Metoprolol Succinate

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Approved

                            Sponsor : Eris Pharmaceuticals

                            Deal Size : $150.0 million

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Biocon Biologics

                            India arrow
                            BioAsia
                            Not Confirmed

                            Biocon Biologics

                            India arrow
                            BioAsia
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Trastuzumab

                            Therapeutic Area : Oncology

                            Study Phase : Approved

                            Sponsor : Sandoz B2B

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            Biocon Biologics Partners with Sandoz for Biosimilars

                            Details : The partnership seeks to enhance the commercialization efforts of Ogivri (trastuzumab), an FDA-approved biosimilar utilized in patients diagnosed with breast cancer or metastatic stomach cancer.

                            Product Name : Ogivri

                            Product Type : Large molecule

                            Upfront Cash : Undisclosed

                            February 10, 2024

                            Lead Product(s) : Trastuzumab

                            Therapeutic Area : Oncology

                            Highest Development Status : Approved

                            Sponsor : Sandoz B2B

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Biocon Biologics

                            India arrow
                            BioAsia
                            Not Confirmed

                            Biocon Biologics

                            India arrow
                            BioAsia
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Everolimus

                            Therapeutic Area : Oncology

                            Study Phase : Approved

                            Sponsor : Eris Lifesciences

                            Deal Size : $43.8 million

                            Deal Type : Divestment

                            DEALS_DEV arrow-down

                            Biocon Biologics Announces Divestment of Two Non-Core Branded Formulations

                            Details : Through the divestment, Eris gains Biocon's Dermatology and Nephrology branded formulations business units in India that mostly comprised of its legacy small molecules’ brands, including Advacan (everolimus), an anti-cancer medicine.

                            Product Name : Advacan

                            Product Type : Small molecule

                            Upfront Cash : Undisclosed

                            November 09, 2023

                            Lead Product(s) : Everolimus

                            Therapeutic Area : Oncology

                            Highest Development Status : Approved

                            Sponsor : Eris Lifesciences

                            Deal Size : $43.8 million

                            Deal Type : Divestment

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth